Aetion

New eBook: The role of real-world evidence in FDA approvals. Download now.

COVID-19 conversation and collaboration

Aetion is committed to advancing COVID-19 research through our work with industry, including FDA, biopharma, and working groups such as the COVID-19 Evidence Accelerator. This page features a snapshot of our and our collaborators’ latest thinking on how real-world data can inform understanding of and response to coronavirus disease.

Usage of medications in-hospital

This chart—generated in Real-Time Insights and Evidence, a solution powered by Aetion and HealthVerity—shows U.S. hospital visits over time, with corresponding use of common medicines used to treat COVID-19.

https://aetion.com/wp-content/uploads/2020/11/Screen-Shot-2020-12-07-at-12.20.53-PM.png

Latest news

December 21, 2020

SARS-CoV-2 antibodies can protect from reinfection, NCI study suggests

National Cancer Institute

December 8, 2020

‘Unpredictable pathogen’: New coronavirus study highlights severity of illness

Global News

October 29, 2020

Generating real-world evidence from chargemaster data: Q&A with Myla Maloney of Premier, Inc.

October 15, 2020

Unite and conquer approach finds shared weaknesses of coronaviruses

BioWorld

September 24, 2020

Ask the Accelerators: Dr. William Morice of Mayo Clinic Laboratories on RWE and COVID-19 diagnostics

September 18, 2020

Data-driven approach to COVID-19 requires rigor, transparency

S&P Global

See more news

Real-Time Insights & Evidence

A COVID-ready solution powered by Aetion and HealthVerity

Learn more

The Evidence Digest

Subscribe to our newsletter for insights and updates on research and applications for real-world evidence in life sciences and value-based health care.